272 related articles for article (PubMed ID: 30140908)
1. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
[TBL] [Abstract][Full Text] [Related]
2. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
3. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
[TBL] [Abstract][Full Text] [Related]
4. The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma.
Sun W; Di L; Chen L; Li D; Wu Y; Xiang J; Zhou S; Sun T
BMC Surg; 2022 Nov; 22(1):374. PubMed ID: 36324095
[TBL] [Abstract][Full Text] [Related]
5. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of surgery and radioiodine treatment for neck recurrence in papillary thyroid cancer.
Kalaitzidou S; Papadakis G; Sapera A; Tampouratzi D; Drosou A; Triantafillou E; Kotis M; Aravantinou A; Roumpidaki Z; Gkioxaris V; Karavasili C; Dracopoulou A; Kaltzidou V; Veniou I; Karelas I; Stampouloglou P; Sarof P; Petridis N; Papadouli D; Iordanidou L; Trivizaki E; Manikis P; Efstathiou I; Tertipi A
J BUON; 2020; 25(1):383-388. PubMed ID: 32277658
[TBL] [Abstract][Full Text] [Related]
7. Utility of Early Postoperative Unstimulated Thyroglobulin in Influencing Decision Making in Patients with Papillary Thyroid Carcinoma.
McDow AD; Shumway CM; Pitt SC; Schneider DF; Sippel RS; Long KL
Ann Surg Oncol; 2019 Nov; 26(12):4002-4007. PubMed ID: 31267301
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation.
Yim JH; Kim WB; Kim EY; Kim WG; Kim TY; Ryu JS; Moon DH; Sung TY; Yoon JH; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2011 Dec; 96(12):3695-700. PubMed ID: 21976723
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy.
Jin M; Ahn J; Lee YM; Sung TY; Kim WG; Kim TY; Ryu JS; Kim WB; Shong YK; Jeon MJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):602-609. PubMed ID: 32981302
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
[TBL] [Abstract][Full Text] [Related]
11. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
Llamas-Olier AE; Cuéllar DI; Buitrago G
Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
[TBL] [Abstract][Full Text] [Related]
12. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
[TBL] [Abstract][Full Text] [Related]
13. An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy.
Choi JH; Lim I; Lee I; Byun BH; Kim BI; Choi CW; Lim SM
Ann Nucl Med; 2019 Feb; 33(2):128-134. PubMed ID: 30382500
[TBL] [Abstract][Full Text] [Related]
14. Second Adjuvant Radioiodine Therapy after Reoperation for Locoregionally Persistent or Recurrent Papillary Thyroid Carcinoma.
Cadena-Piñeros E; Escobar JV; Carreño JA; Rojas JG
World J Nucl Med; 2022 Dec; 21(4):290-295. PubMed ID: 36398303
[No Abstract] [Full Text] [Related]
15. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of adjuvant radioactive iodine after reoperation in patients with persistent or recurrent differentiated thyroid cancer: a systematic review.
Raghupathy J; Tan BKJ; Song HJJMD; Chia AZQ; Tan YZ; Yang SP; Parameswaran R
Langenbecks Arch Surg; 2023 Jan; 408(1):21. PubMed ID: 36635455
[TBL] [Abstract][Full Text] [Related]
17. The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation.
Yim JH; Kim WB; Kim EY; Kim WG; Kim TY; Ryu JS; Gong G; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2011 Jul; 96(7):2049-56. PubMed ID: 21508143
[TBL] [Abstract][Full Text] [Related]
18. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.
Lango M; Flieder D; Arrangoiz R; Veloski C; Yu JQ; Li T; Burtness B; Mehra R; Galloway T; Ridge JA
Thyroid; 2013 Sep; 23(9):1099-105. PubMed ID: 23421588
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
20. Predictors of thyroglobulin in the lymph nodes recurrence of papillary thyroid carcinoma undergoing total thyroidectomy.
Xing Z; Qiu Y; Li Z; Zhang L; Fei Y; Zhu J; Su A
BMC Surg; 2021 Jan; 21(1):53. PubMed ID: 33482804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
